GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Tax Provision

BCAL Diagnostics (ASX:BDX) Tax Provision : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Tax Provision?

BCAL Diagnostics's tax provision for the six months ended in Dec. 2023 was A$0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.


BCAL Diagnostics Tax Provision Historical Data

The historical data trend for BCAL Diagnostics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Tax Provision Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23
Tax Provision
- -

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Tax Provision Get a 7-Day Free Trial - - - - -

BCAL Diagnostics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BCAL Diagnostics (ASX:BDX) Business Description

Traded in Other Exchanges
N/A
Address
Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.